Specifically, TGM2 has significant impacts on doxorubicin resistance in cancer treatment [40] and mediates the resistance to neratinib in metastatic breast cancer by up-regulating IL-6 and activating the NF-κB signaling pathways [41]. The gene discussed is TGM2; the disease is cancer.